uniQure Stock Crashed on Its Huntington’s Data. Wall Street’s Price Target Says the Selloff Went Too Far
uniQure (QURE) stock fell 37.33% after its Huntington’s disease gene therapy showed reduced efficacy in four-year data. The consensus price target is $68.20, implying significant upside. The company's value hinges on FDA approval, expected in 2026. Investors reacted to deceleration in therapy effectiveness and missing data.
How this was made
The 30-second read
Why it matters
The four‑year data downgrade reduces confidence in the therapy's efficacy, likely extending the current sell‑off and pressuring biotech risk assets.
Market read
Shares fell 37% on the same day; the move reflects immediate market reaction to the new clinical data.
What to watch
Cash runway to 2030 and potential pricing premium for a first‑in‑class Huntington's therapy may support a longer‑term upside.
Background
uniQure's AMT‑130 is a one‑time gene therapy for Huntington's disease; the company is currently pre‑approval and heavily dependent on FDA clearance.
Ticker impact
uniQure disclosed four-year gene‑therapy data showing slower disease slowing than at three years, triggering a 37% share drop.
likely pressure as the market prices in reduced efficacy and potential regulatory concerns
Data were not statistically significant and missing a large portion of patients, raising doubts ahead of the FDA advisory committee.
Market effects
Biotech sector may see broader risk aversion toward gene‑therapy candidates pending FDA review.
US biotech ETFs could face short‑term pressure, especially those with exposure to rare‑disease pipelines.
Limited to investors tracking rare‑disease therapeutics; no immediate global macro effect.
Counterpoint
If the FDA grants priority review based on three‑year data, the stock could rebound from oversold levels.
Key entities
- companyuniQure
NASDAQ‑listed gene‑therapy developer
- regulatorFDA
U.S. agency expected to review the filing later this year
